Renal injury in neonates: use of 'omics' for developing precision medicine in neonatology
Autor: | Peter J. Giannone, Mina Hanna, John Anthony Bauer, Kelsey A Montgomery, Mandar S. Joshi |
---|---|
Rok vydání: | 2016 |
Předmět: |
Proteomics
medicine.medical_specialty 030232 urology & nephrology MEDLINE Kidney 03 medical and health sciences 0302 clinical medicine 030225 pediatrics medicine Animals Humans Metabolomics Neonatology Precision Medicine Biomarker discovery Intensive care medicine business.industry Infant Newborn Acute kidney injury Kidney metabolism Genomics Acute Kidney Injury Prognosis Precision medicine medicine.disease Omics Treatment Outcome Pediatrics Perinatology and Child Health Personalized medicine business Biomarkers |
Zdroj: | Pediatric Research. 81:271-276 |
ISSN: | 1530-0447 0031-3998 |
Popis: | Preterm birth is associated with increased risks of morbidity and mortality along with increased healthcare costs. Advances in medicine have enhanced survival for preterm infants but the overall incidence of major morbidities has changed very little. Abnormal renal development is an important consequence of premature birth. Acute kidney injury (AKI) in the neonatal period is multifactorial and may increase lifetime risk of chronic kidney disease.Traditional biomarkers in newborns suffer from considerable confounders, limiting their use for early identification of AKI. There is a need to develop novel biomarkers that can identify, in real time, the evolution of renal dysfunction in an early diagnostic, monitoring and prognostic fashion. Use of "omics", particularly metabolomics, may provide valuable information regarding functional pathways underlying AKI and prediction of clinical outcomes.The emerging knowledge generated by the application of "omics" (genomics, proteomics, metabolomics) in neonatology provides new insights that can help to identify markers of early diagnosis, disease progression, and identify new therapeutic targets. Additionally, omics will have major implications in the field of personalized healthcare in the future. Here, we will review the current knowledge of different omics technologies in neonatal-perinatal medicine including biomarker discovery, defining as yet unrecognized biologic therapeutic targets, and linking of omics to relevant standard indices and long-term outcomes. |
Databáze: | OpenAIRE |
Externí odkaz: |